Simple blood test could decide best therapy for advanced lung cancer

NCT ID NCT05715229

Recruiting now Disease control Sponsor: Hackensack Meridian Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether a blood test that tracks tumor DNA can guide treatment for people with advanced non-small cell lung cancer. Participants will receive either immunotherapy alone or immunotherapy plus chemotherapy, based on their blood test results. The goal is to see if this personalized approach improves how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Nivolumab (Opdivo), Ipilimumab (Yervoy), Carboplatin, Paclitaxel, Pemetrexed
What this could lead to: If successful, this could help doctors personalize treatment for advanced lung cancer, using a simple blood test to decide who needs only immunotherapy and who needs added chemotherapy.
What could go wrong: This is a phase 2 trial with only 108 participants, so results are preliminary. The blood test may not reliably predict treatment response, and immunotherapy can cause serious immune-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Jersey Shore University Medical Center
NOT_YET_RECRUITING

Neptune City, New Jersey, 07753, United States
John Theurer Cancer Center, Hackensack Meridian Health
RECRUITING

Hackensack, New Jersey, 07410, United States
Lombardi Comprehensive Cancer Center, Georgetown University
NOT_YET_RECRUITING

Washington D.C., District of Columbia, 20007, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.